Latest Tax Incentives News

Page 5 of 64
Immutep has identified structural differences between the efti used in its failed TACTI-004 Phase III trial and batches used in earlier successful studies, prompting a new 200 L manufacturing run. The biotech is narrowing efti’s future development focus while elevating autoimmune candidate IMP761 to co-priority status.
Ada Torres
Ada Torres
29 Oct 2026
Cambium Bio has moved Elate Ocular into Phase 3 manufacturing and submitted an updated CAMOMILE-2 protocol to the FDA. The company is targeting First Patient In by year-end, but that timetable depends on a conditional A$7.1 million placement, unsigned CRO agreements and release of the first clinical batch.
Ada Torres
Ada Torres
28 Oct 2026
Right Resources has moved its Blue gold-tungsten project from surface mapping to its first subsurface test, with assays due in the December quarter. The exploration milestone comes alongside a tighter funding position, with reported cash coverage of 1.90 quarters and further financing under consideration.
Maxwell Dee
Maxwell Dee
28 Oct 2026
PainChek is concentrating its commercial effort on residential aged care after signing new US and UK business, including an 808-licence Sabra expansion and an approximately 1,800-licence Hallmark contract. Revenue and retention improved, but activated ARR growth slowed to 1.2% for the quarter and cash covered an estimated 2.5 quarters of historical operating outflows.
Victor Sage
Victor Sage
28 Oct 2026
Hastings Technology Metals has completed its 49% acquisition of a Thai hydrometallurgical plant, with upgrades targeting 12,000 tonnes per annum of Mixed Rare Earth Chloride output. The company now faces the harder test: commissioning the facility, securing customers and converting a contracted feedstock position into sales.
Victor Sage
Victor Sage
28 Oct 2026
Avecho has resumed recruitment for the final cohort of its pivotal Phase III insomnia trial after an interim review supported continuing at the original 519-participant target. The biotechnology company is also pursuing international licensing while holding $5.3 million in cash.
Ada Torres
Ada Torres
28 Oct 2026
RooLife Group opened FY2027 with A$7.9 million in unaudited revenue and customer cash receipts up 884% year on year. The stronger quarter comes as its Aurora renewable energy division shifts from acquisition and product development towards project execution, although operating cash flow remains negative.
Victor Sage
Victor Sage
28 Oct 2026
Zimi has moved its next-generation Matter smart-home range closer to certification and production, while securing access to more than 10,000 retail outlets through Directed. But the company ended September with $344,000 in cash after burning $714,000 on operations, leaving further funding firmly in the frame.
Sophie Babbage
Sophie Babbage
28 Oct 2026
Latrobe Magnesium has completed its fully underwritten $3.4 million entitlement offer, with sub-underwriters absorbing roughly 91% of the available shares. The company says the funding carries its Victorian demonstration plant through to targeted first magnesium production by the end of 2026.
Victor Sage
Victor Sage
28 Oct 2026
archTIS has reached a significant cash conversion milestone, with quarterly customer receipts exceeding operating payments for the first time since its Spirion acquisition. The cybersecurity company also reported higher margins, lower costs and fresh U.S. defence work, although its most closely watched enterprise licence remains unsigned.
Victor Sage
Victor Sage
28 Oct 2026
Sea Forest lifted first-quarter revenue 67% to A$3.4 million and generated a small operating cash inflow as it transitioned to a new distribution arrangement with Teys Australia. The agreement carries an indicative target of 480,000 cattle by June 2027, but the volume is not guaranteed and remains subject to implementation conditions.
Victor Sage
Victor Sage
28 Oct 2026
Amplia Therapeutics is preparing the next stage of narmafotinib’s pancreatic cancer development as its ACCENT trial nears completion and a Lilly collaboration broadens the drug’s potential into lung cancer. The biotech ended September with $20.8 million in cash, rising to $25.6 million pro forma after an October R&D tax refund.
Victor Sage
Victor Sage
28 Oct 2026

Browse the archive

Full archive